Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars…
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
Zurich targets Beazley to lead global speciality market
The bid was £7.7bn ($10.3bn) as of 19 January 2025, which would make it one of the largest…